The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Subscribe To Our Newsletter & Stay Updated
